2023

• 15 Jun 2023
  NDWG Newsletter - February 2023
• 14 Jun 2023
  NDWG Newsletter - March 2023
• 14 Jun 2023
  NDWG Newsletter - June 2023
• 8 Jun 2023
  A scoping review on the risk of TB in specific population groups
• 8 Jun 2023
  Are mRNA based transcriptomic signatures ready for diagnosing TB in the clinic
• 25 Apr 2023
  BCG vaccines
• 25 Apr 2023
  Roadmap towards ending TB in children and adolescents 2nd Edition (RUS)
• 25 Apr 2023
  Roadmap towards ending TB in children and adolescents 2nd Edition (FR)
• 24 Apr 2023
  Summary Guidance POSEE 2021
• 24 Apr 2023
  Research Priorities for Paedriatic Tuberculosis
• 24 Apr 2023
  Management of Multidrug-Resistant Tuberculosis in Children
• 24 Apr 2023
  Guidelines on the management of latent Tuberculosis Infections.
• 24 Apr 2023
  Guidance for National Tuberculosis Programmes
• 24 Apr 2023
  Best Practices in Child and Adolescent Tuberculosis Care
• 24 Apr 2023
  A Research Agenda fro Childhood Tuberculosis
• 20 Apr 2023
  TB-PPM Learning Network
• 19 Apr 2023
  Newsletter Mini-Meet PPM 2021
• 19 Apr 2023
  Agenda Mini-Meet May 2021
• 19 Apr 2023
  News Anual Meeting PPM 2019
• 19 Apr 2023
  Newsletter Anual Meeting PPM 2020
• 19 Apr 2023
  Newsletter Anual Meeting PPM 2021
• 12 Apr 2023
  Guidelines on TB preventive treatment
• 11 Apr 2023
  GUIDE TO DEVELOP A NATIONAL ACTION PLAN ON PUBLIC-PRIVATE MIX
• 11 Apr 2023
  Agenda Anual Meeting 2020
• 11 Apr 2023
  Day 1
• 11 Apr 2023
  Agenda Anual Meeting 2021
• 11 Apr 2023
  Day 2
• 11 Apr 2023
  Day 1
• 4 Apr 2023
  Final Report Anual Meeting 2016
• 3 Apr 2023
  Final Report Anual Meeting 2015
• 3 Apr 2023
  Agenda Anual Meeting 2015
• 3 Apr 2023
  Report of the annual meeting of the childhood TB Subgroup 2016
• 16 Mar 2023
  May 2022 LabCoP Extended ECHO Session Flyer
• 16 Mar 2023
  March 2023 LabCoP ECHO Session Flyer
• 15 Mar 2023
  GLI Practical Guide to TB Laboratory Strengthening
• 14 Mar 2023
  Checklist TB Interventions GF proposals
• 9 Mar 2023
  Engaging Private Health Care Providers in TB Care and Prevention: A landscape Analysis 2nd Edition
• 9 Mar 2023
  Public–private mix for TB prevention and care: a roadmap
• 8 Mar 2023
  Line probe assays for detection of drug-resistant tuberculosis
• 8 Mar 2023
  Practical manual of processing stool samples for diagnosis of childhood TB
• 8 Mar 2023
  Manual for selection of molecular WHOrecommended rapid diagnostic tests for detection of tuberculosis and drug-resistant tuberculosis
• 8 Mar 2023
  Two years post UN General Assembly High-Level Meeting on the fight against tuberculosis: advances and setbacks in high drug-resistant TB burden countries
• 8 Mar 2023
  Roadmap towards ending TB in children and adolescents 2nd Edition
• 13 Feb 2023
  Upper Room GUV maintenance (Spanish)
• 13 Feb 2023
  Terms of Reference ETTi
• 13 Feb 2023
  Upper Room GUV maintenance (Chinese
• 13 Feb 2023
  Upper Room GUV maintenance (Russian)
• 7 Feb 2023
  ETTI IPC workshop SA 2022 Overview
• 12 Jan 2023
  Line probe assays for detection of drug-resistant tuberculosis: interpretation and reporting manual for laboratory staff and clinicians

  This document was developed to provide practical guidance on interpretation of the most commonly used first- and second-line line probe assays (LPAs). In this updated manual, the interpretation of mutations identified by the assays has been revised to align with the WHO catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. The latest LPA instructions for use of the assays are also presented. Lastly, case studies are provided that support staff at national and regional TB reference laboratories to understand and manage any discrepancies between phenotypic and genotypic drug susceptibility testing results

• 12 Jan 2023
  Manual for selection of molecular WHO recommended rapid diagnostic tests for detection of tuberculosis and drug-resistant tuberculosis

  This manual provides practical guidance on the selection of molecular WHO-recommended rapid diagnostic (mWRD) and drug resistance tests for TB and drug-resistant TB. It is designed to be suitable for use in any country, with a customizable approach that assists users to tailor their selection efforts based on their local context. The document includes a stepwise approach to selection of one or more mWRDs and a decision pathway to follow. It also includes a description of all mWRDs recommended by WHO as of December 2021, as well as key considerations and questions to ask when making a final mWRD selection to best meet patient and program needs.